We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UCG:MILUniCredit S.p.A. Analysis

Data as of 2026-03-09 - not real-time

€65.09

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

UniCredit delivers a solid earnings story, highlighted by a record net profit and operating margin well above 60%, while maintaining a dividend yield near 5% with a comfortable payout ratio. Revenue growth remains positive, and the forward earnings per share is projected to rise, supporting a forward PE that undercuts the industry average. The balance sheet shows ample cash relative to debt, and a return on equity in the high teens, underscoring the bank's profitability and capital strength. Valuation metrics suggest the stock is priced attractively, with a trailing PE far lower than peers and a price‑to‑book ratio below 2.0, while analyst consensus targets sit well above the current market price, implying notable upside.
On the technical side, the 20‑day SMA sits just above the 50‑day SMA, indicating a modest short‑term bias, yet the 200‑day SMA remains lower, providing a supportive backdrop. RSI hovers in the low‑30s, hinting at potential oversold conditions, but the MACD is in bearish territory, tempering momentum expectations. Volume is on an upward trend, and the stock trades near a clear support level, with a sizable resistance ceiling that aligns with recent highs. Elevated 30‑day volatility and a beta below 1 point to moderate market sensitivity, while the “Extreme Greed” sentiment in the fear‑greed index reflects strong investor appetite. Overall, the fundamentals outweigh the mixed technical signals, positioning UniCredit as a compelling buy at current levels.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Oversold RSI suggesting price floor
  • Increasing volume supporting demand
  • Support level near current price

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Fundamental earnings strength and margin expansion
  • Dividend yield above 4% with sustainable payout
  • Analyst target prices indicating ~30% upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Robust capital position and cash generation
  • Strategic presence across diversified European markets
  • Low beta and defensive banking profile

Key Metrics & Analysis

Financial Health

Revenue Growth3.70%
Profit Margin43.58%
P/E Ratio9.4
ROE16.77%
ROA1.33%
P/B Ratio1.4
Op. Cash Flow€8.5B
Industry P/E17.4

Technical Analysis

TrendNeutral
RSI33.9
Support€62.66
Resistance€79.79
MA 20€71.69
MA 50€72.07
MA 200€65.17
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair Value€27.11
Target Price€84.86
Upside/Downside30.37%
GradeUndervalued
TypeBlend
Dividend Yield4.76%

Risk Assessment

Beta0.67
Volatility39.80%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.